Abstrakt

Efficacy of clobazam monotherapy in three cases of symptomatic localization-related epilepsy in children

Toshiyuki Iwasaki, Yutaka Nonoda, Kenji Takei, Nozomi Hosoda and Masahiro Ishii

Clobazam is approved in many countries as an additional antiepileptic drug for the management of intractable epilepsy. However, a number of reports have also described its use as first-line therapy in this indication. In this article, we describe three cases involving children (aged 2–12 years) with symptomatic localization-related and intractable epilepsy who responded to low dosage (0.2–0.4 mg/kg/day) clobazam monotherapy. For periods of 3.1–4.4 years, the treatment was well-tolerated and improved electroencephalogram findings with complete disappearance of clinical convulsions. Thus, low-dose clobazam appears to be a useful treatment option in these difficult-to-manage cases of intractable epilepsy.